Cerebrotendinous Xanthomatoses
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Leadiant BiosciencesMD - Rockville
2 programs1
Chenodeoxycholic acidPhase 31 trial
Chenodeoxycholic AcidN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Leadiant BiosciencesChenodeoxycholic acid
Leadiant BiosciencesChenodeoxycholic Acid
Clinical Trials (2)
Total enrollment: 28 patients across 2 trials
A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)
Start: May 2024Est. completion: Dec 20250
Phase 3Withdrawn
Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)
Start: Dec 2014Est. completion: Jun 201528 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space